Article Text

PDF
Experimental therapeutics—preclinical
P04 A Huntingtin peptide inhibits POLYQ-HHTT associated defects
  1. F Maschat1,
  2. Y Arribat1,
  3. Y Talmat-Amar1,
  4. N Bonneaud1,
  5. C Bauer2,
  6. J Bayle2,
  7. P Maurel2,
  8. M-L Parmentier1
  1. 1Institut de Génomique Fonctionnelle, Montpellier. France
  2. 2Medesis Pharma, Baillargues, France

Abstract

Background Huntington's disease (HD) pathogenesis results from a dominant effect of polyQ-hHtt and a loss of function of Htt. Indeed, addition of wild-type Htt improves polyQ-hHtt-induced defects.

Aims Screening on polyQ-hHtt aggregation in HeLa cells, we identified an inhibitory 23aa peptide (Pep42) lying within human Htt. Interestingly Pep42 acts specifically on HD model through a direct interaction with N17 domain, suggesting a role of Pep42 on nucleation and aggregation processes. The protective properties of Pep42 were confirmed on different polyQ-hHtt-induced phenotypes in HD Drosophila model. Therefore Pep42 presents a clear therapeutical potential that we further tested in R6(2) mice.

Methods/techniques In order to attempt to cross the brain-blood barrier, Pep42 was fused to TAT-HIV. Then, we compared its protective effect after intraventricular injections, intravenous injections, vs buccal and rectal mucosa administrations in a water-in-oil microemulsion-based delivery vector (called Aonys, MedesisPharma).

Results/outcome Pharmacokinetics analysed on brain sections at 6hrs and 24hrs after Pep42 treatment showed a nice spread of the peptide in the brain, still visible at 24 h. Finally, administration of Pep42/Aonys or empty vector was performed daily in 2 wks–11 wks old R6(2) mice for pre-symptomatic treatment and in 9–11 wks old R6(2) mice for post-symptomatic treatment. Several polyQ-hHtt behavioural associated defects were analysed (rotarod, foot-clasping or body weights), and several markers were followed on brain sections. These data globally show the protective effect of Pep42-TAT when delivered through Aonys vector, in both pre- and post-symptomatic treatments.

Conclusions Altogether these data highlight a new therapeutic strategy for HD, associating an efficient peptide with a powerful delivery technology.

  • Inhibitory peptide
  • drosophila
  • mice
  • protein-transduction-domain
  • nanotechnology

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.